Detalhe da pesquisa
1.
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.
N Engl J Med
; 385(20): 1856-1867, 2021 11 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34534429
2.
Disentangling the reasons why older adults do not readily participate in cancer trials: a socio-epidemiological mixed methods approach.
Age Ageing
; 53(2)2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38346934
3.
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 24(4): 392-402, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36878237
4.
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Gynecol Oncol
; 171: 106-113, 2023 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36868112
5.
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gynecol Oncol
; 170: 186-194, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36706645
6.
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Lancet Oncol
; 23(11): 1367-1377, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-36183733
7.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med
; 381(25): 2416-2428, 2019 12 19.
Artigo
Inglês
| MEDLINE | ID: mdl-31851799
8.
Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study.
Gynecol Oncol
; 165(1): 40-48, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35115180
9.
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Lancet Oncol
; 22(2): 267-276, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33539744
10.
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Breast Cancer Res
; 23(1): 31, 2021 03 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33676547
11.
Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study.
Breast Cancer Res
; 23(1): 9, 2021 01 19.
Artigo
Inglês
| MEDLINE | ID: mdl-33468209
12.
Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
Br J Cancer
; 124(4): 777-785, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33191407
13.
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).
Angiogenesis
; 23(2): 193-202, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31773439
14.
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Gynecol Oncol
; 159(1): 256-263, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32712155
15.
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial.
Breast Cancer Res
; 21(1): 121, 2019 11 14.
Artigo
Inglês
| MEDLINE | ID: mdl-31727113
16.
Correction to: Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site.
Br J Cancer
; 128(9): 1790, 2023 May.
Artigo
Inglês
| MEDLINE | ID: mdl-37055522
17.
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Gynecol Oncol
; 175: 194, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37271667
18.
Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution.
Support Care Cancer
; 26(12): 4097-4103, 2018 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-29855772
19.
Pattern of relapse in low-risk breast cancer patients followed within a community care network.
Breast J
; 23(6): 687-693, 2017 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-28556478
20.
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Lancet Oncol
; 16(13): 1324-34, 2015 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-26342236